Profile
| Role | Director, 10% Owner |
|---|---|
| Notability | 30/100 |
Updated Jul 16, 2026
Fairmount Funds Management LLC has filed 8 SEC Form 4 filings across 6 companies in the last 90 days — active on both sides. Lifetime open-market purchases: $54.01M. Lifetime open-market sales: $1.20B. Historical track record: 4/5 stars across 3 tracked purchases.
| Role | Director, 10% Owner |
|---|---|
| Notability | 30/100 |
InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realised performance after each tracked open-market purchase.
| InsiderAlpha rating | ★★★★☆ (4/5) |
|---|---|
| Total purchases tracked | 3 |
| Purchases with forward-return data | 3 |
| 30-day win rate | 6667% |
| 90-day win rate | 6667% |
| Avg 5-day return | +1571.43% |
| Avg 30-day return | +1841.48% |
| Avg 90-day return | +1798.31% |
| Best 30-day return | +5568.35% |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-02 | ORKA | Oruka Therapeutics, Inc. | S — Open-market sale | 3.55M | $84.43 | $300.01M |
| 2026-07-02 | ORKA | Oruka Therapeutics, Inc. | J — Other acquisition / disposition | 3.55M | — | |
| 2026-06-24 | SYRE | Spyre Therapeutics, Inc. | S — Open-market sale | 4.68M | $85.31 | $399.66M |
| 2026-06-24 | SYRE | Spyre Therapeutics, Inc. | J — Other acquisition / disposition | 666.7K | — | |
| 2026-05-13 | VRDN | Viridian Therapeutics, Inc.\DE | P — Open-market purchase | 1.18M | $17.00 | $20.00M |
| 2026-04-01 | ZBIO | Zenas BioPharma, Inc. | P — Open-market purchase | 150.0K | $20.00 | $3.00M |
| 2026-04-01 | COGT | Cogent Biosciences, Inc. | S — Open-market sale | 7.00M | $34.66 | $242.62M |
| 2026-04-01 | COGT | Cogent Biosciences, Inc. | J — Other acquisition / disposition | 7.00M | — | |
| 2026-02-12 | DMRA | Damora Therapeutics, Inc. | M — Option exercise | 2.90M | $0.00 | |
| 2026-02-12 | DMRA | Damora Therapeutics, Inc. | M — Option exercise | 5.81M | $0.00 | |
| 2026-01-23 | COGT | Cogent Biosciences, Inc. | S — Open-market sale | 3.50M | $36.40 | $127.40M |
| 2026-01-23 | APGE | Apogee Therapeutics, Inc. | S — Open-market sale | 1.75M | $76.30 | $133.53M |
| 2025-10-07 | ZBIO | Zenas BioPharma, Inc. | P — Open-market purchase | 316.2K | $19.00 | $6.01M |
| 2025-10-06 | JBIO | Jade Biosciences, Inc. | A — Grant or award | 1.33M | $9.14 | $12.18M |
| 2025-09-17 | ORKA | Oruka Therapeutics, Inc. | A — Grant or award | 333.3K | $15.00 | $5.00M |
| 2025-07-10 | COGT | Cogent Biosciences, Inc. | P — Open-market purchase | 2.78M | $9.00 | $25.00M |
| 2024-11-21 | ORKA | Oruka Therapeutics, Inc. | M — Option exercise | 160.0K | — | |
| 2024-10-01 | DNTH | Dianthus Therapeutics, Inc. /DE/ | J — Other acquisition / disposition | 62.1K | $0.00 |
Fairmount Funds Management LLC is a corporate insider — currently tracked as Director, 10% Owner of Oruka Therapeutics, Inc. (ORKA). InsiderAlpha tracks every SEC Form 4 filing in real time.
8 primary Form 4 filings in the last 90 days, covering 6 companies.
Recorded transactions: 4 open-market purchases ($54.01M) and 5 open-market sales ($1.20B) across all tracked filings.
Across 3 tracked purchases, Fairmount Funds Management LLC averaged +1841.5% avg 30-day return with a 6667% 30-day win rate. InsiderAlpha rates the track record at 4/5 stars.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Fairmount Funds Management LLC profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.